TARGET for NSCLC: Genomic Pathways and Use of EGFR Therapies
The goal of this initiative is to increase clinicians’ knowledge and improve their competence in understanding the latest advances in targeting genomic pathways for the treatment of non-small cell lung cancer (NSCLC) through a review of the current and ongoing research/clinical trials focused on new and emerging EGFR-based therapies.
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.